Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Rigel Pharmaceuticals Inc.
DescriptionJanus kinase-3 inhibitor
Molecular Target Janus kinase-3 (JAK-3)
Mechanism of ActionJanus kinase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationOrgan transplant rejection
Indication DetailsPrevent organ transplant rejection
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today